NextCure, Inc. Share Price
NXTCNextCure, Inc. Stock Performance
Open $13.43 | Prev. Close $13.50 | Circuit Range N/A |
Day Range $13.34 - $13.50 | Year Range $0.22 - $15.61 | Volume 1,932 |
Average Traded $13.47 |
NextCure, Inc. Share Price Chart
About NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
NextCure, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
02-Jan-26 | $13.43 | $13.41 | -6.68% |
31-Dec-25 | $13.99 | $14.37 | +3.16% |
30-Dec-25 | $13.93 | $13.93 | +12.07% |
23-Dec-25 | $12.27 | $12.43 | +8.23% |
22-Dec-25 | $11.48 | $11.48 | +0.53% |
19-Dec-25 | $10.65 | $11.43 | +5.59% |
17-Dec-25 | $10.82 | $10.82 | -0.55% |